Download FREE Report Sample
Download Free sampleHemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Hemophilia Gene Therapy Market contains market size and forecasts of Hemophilia Gene Therapy in Global, including the following market information:
Global Hemophilia Gene Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hemophilia Gene Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hemophilia A Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hemophilia Gene Therapy include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure and Freeline Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hemophilia Gene Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia Gene Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hemophilia Gene Therapy Market Segment Percentages, by Type, 2021 (%)
Hemophilia A
Hemophilia B
Global Hemophilia Gene Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hemophilia Gene Therapy Market Segment Percentages, by Application, 2021 (%)
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
Global Hemophilia Gene Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hemophilia Gene Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia Gene Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hemophilia Gene Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
